Trial Profile
A Phase II, Double-Blinded, Randomized Evaluation of Femara (Letrozole) Versus Placebo for Adjuvant Treatment After Completion of First-Line Chemotherapy for Patients With Optimally Debulked and Chemoresponsive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Letrozole (Primary) ; Platinum complexes
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 19 Apr 2016 Status changed from discontinued to withdrawn prior to enrolment as no registration and the drug company sponsor withdrew support
- 23 Mar 2009 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
- 13 Mar 2009 Actual end date (Sep 2008) added as reported by ClinicalTrials.gov.